Molecular Monitoring of Minimal Residual Disease in Acute Myeloblastic Leukemia with t(8;21) by RT-PCR

References

• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.C., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of the acute myeloid leukemia: A report of the French-American-British Co-operative Group. Ann. Intern. Med. 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute myeloid leukemia. Ann. Genet. 1973; 16: 109–112
   PubMedGoogle Scholar
• Raimondi S.C., Kalwinsky D.K., Hayashi Y., Behm F.G., Mirro J., Jr., Williams D.L. Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 1989; 40: 13–27
   PubMed Web of Science ®Google Scholar
• Rowley J.D. Recurring chromosome abnormalities in leukemia and lymphoma. Semin. Hematol. 1990; 27: 122–136
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Rowley J.D. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780–2786
   PubMed Web of Science ®Google Scholar
• Yamasaki H., Era T., Asou N., Sanada I., Matutes E., Yamaguchi K., Takatsuki K. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia. Leukemia 1995; 9: 1147–1153
   PubMed Web of Science ®Google Scholar
• Swirsky D.M., Li Y.S., Matthews J.G., Flemans R.J., Rees J.K., Hayhoe F.G. 8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features. Br. J., Haematol. 1984; 56: 199–213
   PubMed Web of Science ®Google Scholar
• Wheatly K., Bennett A., Goldstone A., Hann I., Stevens R., Rees J., Gray R. A simple robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukemia (AML) derived from the United Kingdom Medical Research Council (MRC) AML 10 trial. Blood 1995; 86: 598a, abstr, suppl. 1
   PubMedGoogle Scholar
• Martinez-Climent J.A., Lane N.J., Rubin C.M., Morgan E., Johnstone H.S., Mick R., Murphy S.B., Vardiman J.W., Larson R.A., Le Beau M.M., et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995; 9: 95–101
   PubMed Web of Science ®Google Scholar
• Erickson P., Gao J., Chang K.S., Look T., Whisenant E., Raimondi S., Lasher R., Trujillo J., Rowley J., Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80: 1825–1831
   PubMed Web of Science ®Google Scholar
• Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., Kamada N., Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 1993; 12: 2715–2721
   PubMed Web of Science ®Google Scholar
• Erickson P.F., Robinson M., Owens G., Drabkin H.A. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res. 1994; 54: 1782–1786
   PubMed Web of Science ®Google Scholar
• Kawasaki E.S., Clark S.S., Coyne M.Y., Smith S.D., Champlin R., Witte O.N., McCormick F.P. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Natl. Acad. Sci. USA 1988; 85: 5698–5702
   PubMed Web of Science ®Google Scholar
• Nucifora G., Larson R.A., Rowley J.D. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712–715
   PubMed Web of Science ®Google Scholar
• Saunders M.J., Tobal K., Liu Yin J.A. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leuk. Res. 1994; 18: 891–895
   PubMed Web of Science ®Google Scholar
• Tobal K., Johnson P.R., Saunders M.J., Harrison C.J., Liu Yin J.A. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br. J. Haematol. 1995; 91: 104–108
   PubMed Web of Science ®Google Scholar
• Tobal K., Saunders M.J., Grey M.R., Liu Yin J.A. Persistence of RARα-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br. J. Haematol. 1995; 90: 615–618
   PubMed Web of Science ®Google Scholar
• Shimizu K., Miyoshi H., Kozu T., Nagata J., Enomoto K., Maseki N., Kaneko Y., Ohki M. Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosome translocation. Cancer Res. 1992; 52: 6045–6948
   PubMedGoogle Scholar
• Tighe J.E., Daga A., Calabi F. Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia. Blood 1993; 81: 592–596
   PubMed Web of Science ®Google Scholar
• Kozu T., Miyoshi H., Shimizu K., Maseki N., Kaneko Y., Asou H., Kamada N., Ohki M. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993; 82: 1270–1276
   PubMed Web of Science ®Google Scholar
• Chang K.S., Fan Y.H., Stass S.A., Estey E.H., Wang G., Trujillo J.M., Erickson P., Drabkin H. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 1993; 8: 983–988
   PubMed Web of Science ®Google Scholar
• Downing J.R., Head D.R., Curcio-Brint A.M., Hulshof M.G., Motroni T.A., Raimondi S.C., Carroll A.J., Drabkin H.A., Willman C., Theil K.S., et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21) (q22;q22) translocation. Blood 1993; 81: 2860–2865
   PubMed Web of Science ®Google Scholar
• Maruyama F., Yang P., Stass S.A., Cork A., Freireich E.J., Lee M.S., Chang K.S. Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogeneous leukemia. Cancer Res. 1993; 53: 4449–4451
   PubMed Web of Science ®Google Scholar
• Nucifora G., Dickstein J.I., Torbenson V., Roulston D., Rowley J.D., Vardiman J.W. Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without t(8;21). Leukemia 1994; 8: 1533–1538
   PubMed Web of Science ®Google Scholar
• Zhang T., Hillion J., Tong J.H., Cao Q., Chen S.J., Berger R., Chen Z. AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblasts leukemia with t(8;21). Leukemia 1994; 8: 729–734
   PubMed Web of Science ®Google Scholar
• Kusec R., Laczika K., Knobl P., Friedl J., Greinix H., Kahls P., Linkesch W., Schwarzinger I., Mitterbauer G., Purtscher B., et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735–739
   PubMed Web of Science ®Google Scholar
• Guerrasio A., Rosso C., Martinelli G., Lo Coco F., Pampinella M., Santoro A., Lanza C., Allione B., Resegotti L., Saglio G. Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continuos clinical remission. Br. J. Haematol. 1995; 90: 364–368
   PubMed Web of Science ®Google Scholar
• Jurlander J., Caligiuri M.A., Ruutu T., Baer M.R., Strout M.P., Oberkircher A.R., Hoffmann L., Ball E.D., Frei-Lahr D.A., Christiansen N.P., Block A.M., Knuutila S., Herzig G.P., Bloomfield C.D. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88: 2183–2191
   PubMed Web of Science ®Google Scholar
• Kwong Y.L., Chan V., Wong K.F., Chan T.K. Use of polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer 1995; 75: 821–825
   PubMed Web of Science ®Google Scholar
• Satake N., Maseki N., Kozu T., Sakashita A., Kobayashi H., Sakurai M., Ohki M., Kaneko Y. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br. J. Haematol. 1995; 91: 892–898
   PubMed Web of Science ®Google Scholar
• Miyamoto T., Nagafuji K., Akashi K., Harada M., Kyo T., Akashi T., Takenaka K., Mizuno S., Gondo H., Okamura T., Dohy H., Nohi Y. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogeneous leukemia. Blood 1996; 87: 4789–4796
   PubMed Web of Science ®Google Scholar
• Saunders M.J., Brereton M.L., Adams J.A., Tobal K., Liu Yin J.A. Persistence of multipotent progenitors expressing AML1/MTG8 transcripts in patients in remission of AML M2 with t(8;21). Br. J. Haematol. 1996; 93: 226, suppl.2
   Google Scholar
• Tighe J.E., Calabi F. Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8,21) of acute myeloid leukemia M2. Blood 1994; 84: 2115–2121
   PubMed Web of Science ®Google Scholar
• van de Locht L.T., Smetsers T.F., Wittebol S., Raymakers R.A., Mensink E.J. Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia. Leukemia 1994; 8: 1780–1784
   PubMed Web of Science ®Google Scholar
• Saunders M.J., Tobal K., Keeney S., Liu Yin J.A. Expression of diverse AML1/MTG8 transcripts is a consistent feature in acute myeloid leukemia with t(8;21) irrespective of disease phase. Leukemia 1996; 10: 1139–1142
   PubMed Web of Science ®Google Scholar
• Tobal K., Yin J.A. Monitoring of minimal residual disease by quantitative reverse transcriptase polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood 1996; 88: 3704–3709
   PubMed Web of Science ®Google Scholar
• Newton J., Tobal K., Liu Yin IA. Peripheral blood as well as bone marrow samples can be used for the quantitation of AML1-MTG8 transcripts to assess effectiveness of treatment and predict relapse. Br. J. Haematol. 1997; 97: 3, suppl. 1
   Google Scholar
• Miyamoto T., Nagafuji K., Harada M., Eto T., Fujisaki T., Kubota A., Akashi K., Mizuno S., Takenaka K., Kanaji T., et al. Quantitative analysis of AML 1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogeneous leukaemia. Br. J. Haematol. 1995; 91: 132–138
   PubMed Web of Science ®Google Scholar
• Muto A., Mori S., Matsushita H., Awaya N., Ueno H., Takayama N., Okamoto S., Kizaki M., Ikeda Y. Serial quantification of minimal residual disease of t(8;21) acute myelogeneous leukemia with RT-competitive PCR assay. Br. J. Haematol. 1996; 95: 85–94
   PubMed Web of Science ®Google Scholar